Validation of a serum screen for alzheimer's disease across assay platforms, species, and tissues

Journal of Alzheimer's Disease

Volumn 42, Issue 4, 2014, Pages 1325-1335

  O'Bryant, Sid E ^a   Xiao, Guanghua ^b   Zhang, Fan ^a   Edwards, Melissa ^c   German, Dwight C ^b   Yin, Xiangling ^d   Como, Tori ^a   Reisch, Joan ^b   Huebinger, Ryan M ^b   Graff Radford, Neill ^e   Dickson, Dennis ^e   Barber, Robert ^a   Hall, James ^a,f   O'Suilleabhain, Padraig ^b   Grammas, Paula ^d  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF NORTH TEXAS   (United States)

^d TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^e MAYO CLINIC   (United States)

^f University of North Texas Health Science Center   (United States)

Author keywords

Alzheimer's disease; blood based biomarkers; serum; species; tissue

Indexed keywords

BIOLOGICAL MARKER; PLASMA PROTEIN;

ADULT; AGED; ALGORITHM; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASSAY PLATFORM; BLOOD SAMPLING; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; IMMUNOFLUORESCENCE TEST; MAJOR CLINICAL STUDY; MALE; MESO SCALE DISCOVERY; MICROVASCULATURE; NONHUMAN; PARKINSON DISEASE; RANDOM SAMPLE; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SUPPORT VECTOR MACHINE; VALIDATION STUDY; ANIMAL; BLOOD; BRAIN; DIFFERENTIAL DIAGNOSIS; DISEASE MODEL; FLUORESCENT ANTIBODY TECHNIQUE; IMAGE PROCESSING; MIDDLE AGED; PATHOLOGY; RECEIVER OPERATING CHARACTERISTIC; TRANSGENIC MOUSE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALGORITHMS; ALZHEIMER DISEASE; ANIMALS; BIOMARKERS; BRAIN; DIAGNOSIS, DIFFERENTIAL; DISEASE MODELS, ANIMAL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MICE, TRANSGENIC; MICROVESSELS; MIDDLE AGED; PARKINSON DISEASE; ROC CURVE; SENSITIVITY AND SPECIFICITY; SUPPORT VECTOR MACHINE;

EID: 84907968763     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-141041     Document Type: Article

References (45)

1. Alzheimer's Association (2012) Alzheimer'sdisease facts and figures. Alzheimers Dement 8, 1-72.
2. Hurd MD, Martorell P, Delavande A, Mullen KJ, Langa KM (2013) Monetary costs of dementia in the United States. N Engl J Med 369, 489-490.
3. Association's Association (2013) 2013 Alzheimer's disease facts and figures. Alzheimers Dement 9, 1-72.
4. Waldemar G, Dubois B, Emre M, Georges J, McKeith IG, Rossor M, Scheltens P, Tariska P, Winblad B, EFNS (2007) Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol 14, e1-e26.
5. Kennard M (1998) Diagnostic markers for Alzheimer's disease. Neurobiol Aging 19, 131-132.
6. Boustani M, Callahan CM, Unverzagt FW, Austrom MG, Perkins AJ, Fultz BA, Hui SL, Hendrie HC (2005) Implementing a screening and diagnosis program for dementia in primary care. J Gen Intern Med 20, 572-577.
7. Cotter VT (2006) Alzheimer's disease: Issues and challenges in primary care. Nurs Clin North Am 41, 83-93.
8. Ray S, Britschqi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici GD, Robinson WH, Sabbagh MN, So YT, Sparks DL, Tabaton M, Tinklenberg J, Yesavage JA, Tibshirani R, Wyss-Coray T (2007) Classification and prediction of clinical Alzheimer's diagnosis based onplasma signaling proteins. Nat Med 13, 1359-1362.
9. Soares HD, Chen Y, Sabbagh M, Roher A, Schrijvers E, Breteler M (2009) Identifying early markers of Alzheimer's disease using quantitative multiplex proteomic immunoassay panels. Ann NY Acad Sci 1180, 56-76.
10. Booij BB, Lindahl T, Wetterberg P, Skaane NV, Saebo S, Feten G, Rye PD, Kristiansen LI, Hagen N, Jensen M, Bardsen K, Winblad B, Sharma P, Lonneborg A (2011) Agene expression patternin blood for the early detectionofAlzheimer's disease. J Alzheimers Dis 23, 109-119.
11. Buerger K, Ernst A, Ewers M, Uspenskaya O, Omerovic M, Morgenthaler NG, Knauer K, Bergmann A, Hampel H (2009) Blood-based microcirculation markers in Alzheimer's disease-diagnostic value of midregional pro-atrial natriuretic peptide/C-terminal endothelin-1 precursor fragment ratio. Biol Psychiatry 65, 979-984.
12. Laske C, Leyhe T, Stransky E, Hoffmann N, Fallgatter AJ, Dietzsch J (2011) Identification of a blood-based biomarker panelfor classificationofAlzheimer'sdisease. Int J Neuropsychopharmacol 14, 1147-1155.
13. O'Bryant SE, Xiao G, Barber R, Reisch J, Hall J, Cullum CM, Doody R, Fairchild T, Adams P, Wilhelmsen K, Diaz-Arrastia R, Texas Alzheimer's Research and Care Consortium (2011) A blood-based algorithm for the detection of Alzheimer's disease. Dement Geriatr Cogn Disord 32, 55-62.
14. Laske C, Schmohl M, Leyhe T, Stransky E, Maetzler W, Berg D, Fallgatter AJ, Joos T, Dietzsch J (2013) Immune profiling in blood identifies sTNF-R1 performing comparably well as biomarker panels for classification of Alzheimer's disease patients. J Alzheimers Dis 34, 367-375.
15. O'Bryant SE, Xiao G, Barber R, Reisch J, Doody R, Fairchild T, Adams P, Waring S, Diza-Arrastia R, Texas Alzheimer's Research Consortium (2010) A serum protein-based algorithm for the detection of Alzheimer disease. Arch Neurol 67, 1077-1081.
16. O'Bryant SE, Xiao G, Barber R, Huebinger R, Wilhelmsen K, Edwards M, Graff-Radford N, Doody R, Diaz-Arrastia R, Texas Alzheimer's Research, Care Consortium, Alzheimer's Disease Neuroimaging, Initiative (2011) A blood-based screening tool for Alzheimer's disease that spans serum and plasma: Findings from TARC and ADNI. PLoS One 6, e28092.
17. O'Bryant SE, Xiao G, Edwards M, Devous M, Gupta VB, Martins R, Zhang F, Barber R, Texas Alzheimer's Research and Care Constortium (TARCC) (2013) Biomark-ers of Alzheimer's disease among Mexican Americans. J Alzheimers Dis 34, 841-849.
18. Nagele E, Han M, DeMarshall C, Belinka B, Nagele R (2011) Diagnosis of Alzheimer's disease based on disease-specific autoantibody profiles in human sera. PLoS One 6, e23112.
19. Reddy MM, Wilson R, Wilson J, Connell S, Gocke A, Hynan L, German D, Kodadek T (2011) Identification of candidate IgG biomarkers for Alzheimer's disease via combinatorial library screening. Cell 144, 132-142.
20. Doecke JD, Laws SM, Faux NG, Wilson W, Burnham SC, Lam CP, Mondal A, Bedo J, Bush AI, Brown B, De Ruyck K, Ellis KA, Fowler C, Gupta VB, Head R, Macaulay SL, Pertile K, Rowe CC, Rembach A, Rodrigues M, Rumble R, Szoeke C, Taddei T, Trounson B, Ames D, Masters CL, Martins RN, Alzheimer's Disease Neuroimaging Initiative, Australian Imaging Biomarker and Lifestyle Research Group (2012) Blood-based protein biomarkers for the diagnosis of Alzheimer's disease. Arch Neurol 69, 1318-1325.
21. Mapstone M, Cheema AK, Fiandaca MS, Zhong X, Mhyre TR, MacArthur LH, Hall WJ, Fisher SG, Peterson DR, Haley JM, Nazar MD, Rich SA, Berlau DJ, Peltz CB, Tan MT, Kawas CH, Federoff HJ (2014) Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med 20, 415-418.
22. Hu WT, Holtzman DM, Fagan AM, Shaw LM, Perrin R, Arnold SE, Grossman M, Xiong C, Craig-Schapiro R, Clark CM, Pickering E, Kuhn M, Chen Y, Van Deerlin VM, McCluskey L, Elman L, Karlawish J, Chen-Plotkin A, Hurtig HI, Siderowf A, Swenson F, Lee VM, Morris JC, Trojanowski JQ, Soares H, Alzheimer's Disease Neuroimaging Initiative (2012) Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology 79, 897-905.
23. Kiddle SJ, Sattlecker M, Proitsi P, Simmons A, Westman E, Bazenet C, Nelson SK, Williams S, Hodges A, Johnston C, Soininen H, Kloszewska I, Mecocci P, Tsolaki M, Vellas B, Newhouse S, Lovestone S, Dobson RJB (2014) Candi date blood proteome markers of Alzheimer's disease onset and progression: A systematic review and replication study. J Alzheimers Dis 38, 515-531.
24. Sabbagh JJ, Kinney JW, Cummings JL (2013) Alzheimer's disease biomarkers: Correspondence between human studies and animal models. Neurobiol Dis 56, 116-130.
25. McKhann D, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's dis ease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
26. Bjerke M, Portelius E, Minthon L, Wallin A, Anckarsater H, Anckarsater R, Andreasen N, Zetterberg H, Andreasson U, Blennow K (2010) Confounding factors influencing amyloid beta concentration in cerebrospinal fluid. Int J Alzheimers Dis 2010, 1-11.
27. Kounnas MZ, Danks AM, Cheng S, Tyree C, Ackerman E, Zhang X, Ahn K, Nguyen P, Comer D, Mao L, Yu C, Pleynet D, Digregorio PJ, Velicelebi G, Stauderman KA, Comer WT, Mobley WC, Li YM, Sisodia SS, Tanzi RE, Wagner SL (2010) Modulation of-y-secretase reduces fj-amyloid deposition in a transgenic mouse model of Alzheimer's disease. Neuron 67, 769-780.
28. Kuhle J, Regeniter A, Leppert D, Mehling M, Kappos L, Lindberg RL, Petzold A (2010) A highly sensitive elec-trochemiluminescence immunoassay for the neurofilament heavy chain protein. J Neuroimmunol 220, 114-119.
29. Oh ES, Mielke MM, Rosenberg PB, Jain A, Fedarko NS, Lyketsos CG, Mehta PD (2010) Comparison of conventional ELISA with electrochemiluminescence technology for detection of amyloid-fj in plasma. J Alzheimers Dis 21, 769-773.
30. Alves G, Bronnick K, Aarsland D, Blennow K, Zetterberg H, Ballard C, Kurz MW, Andreasson U, Tysnes OB, Larsen JP, Mulugeta E (2010) CSF amyloid-fj and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: The Norwegian Park West study. J Neurol Neurosurg Psychiatry 81, 1080-1086.
31. Tripathy D, Sanchez A, Yin X, Luo J, Martinez J, Grammas P (2013) Thrombin as a mediator of cerebrovascular inflammation in AD and hypoxia. Front Aging Neurosci 5, 19.
32. Grammas P, Tripathy D, Sanchez A, Yin X, Luo J (2011) Brain microvasculature and hypoxia-related proteins in Alzheimer's disease. Int J Clin Exp Pathol 4, 616-627.
33. Breiman L (2001) Random forests. Machine Learning 45, 5-32.
34. Dickstein DL, Walsh J, Brautigam H, Stockton SD Jr, Gandy S, Hof PR (2010) Role of vascular risk factors and vascular dysfunction in Alzheimer's disease. Mt Sinai J Med 77, 82-102.
35. Piazza F, Galimberti G, Conti E, Isella V, Perlangeli MV, Speranza T, Borroni B, Pogliani EM, Padovani A, Fer-arese C (2010) Increased tissue factor pathway inhibitor and homocysteine in Alzheimer's disease. Neurobiol Aging 33, 226-233.
36. Okereke OI, Selkoe DJ, Pollak MN, Stampfer MJ, Hu FB, Hankinson SE, Grodstein F (2009) A profile of impaired insulin degradation in relation to late-life cognitive decline: A preliminary investigation. Int J Geriatr Psychiatry 24, 177-182.
37. van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM (2006) Plasma Abeta (1-40) and Abeta (1-42) and the risk of dementia: A prospective case-cohort study. Lancet Neurol 5, 655-660.
38. Schneider P, Hampel H, Buerger K (2009) Biological marker candidates of Alzheimer's disease in blood, plasma, and serum. CNS Neurosci Ther 15, 358-374.
39. Bond J, Graham N, Padovani A, Mackell J, Knox S, Atkinson J (2010) Screening for cognitive impairment, Alzheimer's disease and other dementias: Opinions of European caregivers, payors, physicians and the general public. JNutr Health Aging 14, 558-562.
40. Lo A, Ryder K, Shorr RI (2005) Relationship between patient age and duration of physician visit in ambulatory setting: Does one size fit all? J Am Geriatr Soc 53, 1162-1167.
41. Huebinger R, Xiao G, Wilhelmsen K, Diaz-Arrastia R, Zhang F, O'Bryant SE, Barber R (2012) Comparison of protein con-centrationsinserum versus plasma from Alzheimer's patients. Adv Alzheimers Dis 1, 51-58.
42. Grammas P, Ovase R (2001) Inflammatory factors are elevated inbrain microvesselsin Alzheimer's disease. Neurobiol Aging 22, 837-842.
43. Thirumangalakudi L, Samany PG, Owoso A, Wiskar B, Grammas P (2006) Angiogenic proteins are expressed by brain blood vessels in Alzheimer's disease. J Alzheimers Dis 10, 111-118.
44. Sakamoto N, Hoshino Y, Misaka T, Mizukami H, Suzuki S, Sugimoto K, Yamaki T, Kunii H, Nakazato K, Suzuki H, Saitoh S, Takeishi Y (2013) Serum tenascin-C level is associated with coronary plaque rupture in patients with severe acute coronary syndrome. Heart Vessels 29, 165-170.
45. - (1998) Consensus report of the Working Group on: Molecular and Biochemical Markers of Alzheimer's Disease. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol Aging 19, 109-116.